IL5 and allergic bronchopulmonary aspergillosis: Recent reports have demonstrated the efficacy of mepolizumab, a monoclonal antibody against interleukin (IL)‐5, in the treatment of ABPA; however, there have also been several case reports of treatment failure with mepolizumab for mucoid impaction in ABPA.4